GPX4 and neoplasm: Depletion of both HJURP and PRDX1 led to a greater inhibitory effect on C4-2 cell growth induced by PACMA31 (71.0 % inhibition of xenograft tumor weight and 76.4 % inhibition of xenograft tumor volume), a stable GPX4 inhibitor in vivo [30], compared to the effects of the depletion of either HJURP (51.0 % inhibition of xenograft tumor weight and 61.0 % inhibition of xenograft tumor volume) or PRDX1 (54.2 % inhibition of xenograft tumor weight and 62.5 % inhibition of xenograft tumor volume) alone (Fig. 6A–D).